Enovis Corporation (ENOV) Dividend History

Enovis Corporation (ENOV) is a global medical device company specializing in orthopedics, regenerative medicine, and surgical solutions. It provides innovative products designed to improve patient outcomes and enhance healthcare. The company focuses on delivering surgical instruments, implants, and regenerative therapies across various medical specialties.

2711 Centerville Road, Wilmington, DE, 19808
Phone: (302) 252-9160
Website: https://www.enovis.com

Dividend History

Enovis Corporation currently does not pay dividends

Company News

  • The orthopedic braces and supports market is projected to grow at a CAGR of 5.04% from 2024 to 2030, driven by the increasing burden of orthopedic conditions, sports-related injuries, and the development of smart and custom-made braces.

    GlobeNewswire Inc.
  • Enovis has introduced the AltiVate Reverse Glenoid System, a new solution for reverse shoulder arthroplasty. The system offers modular and augmented baseplates, providing surgeons with more options to improve implant longevity and optimize patient outcomes.

    Zacks Investment Research
  • In the latest quarter, 6 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 2 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $78.67, with a high estimate of $82.00 and a low estimate of $72.00. Surpassing the previous average price target of $73.00, the current average has increased by 7.77%. Breaking Down Analyst Ratings: A Detailed Examination A comprehensive examination of how financial experts perceive Enovis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Maintains Buy $82.00 - Mike Matson Needham Maintains Buy $82.00 - Vik Chopra Wells Fargo Raises Overweight $79.00 $73.00 Caitlin Cronin Canaccord Genuity Raises Buy $75.00 $73.00 Mike Matson Needham Raises Buy $82.00 $73.00 George Sellers Stephens & Co. Announces Overweight $72.00 - Key Insights: Action Taken: Analysts respond ...Full story available on Benzinga.com

    Benzinga
Page data last updated 07/23/2025 05:07:30 UTC